Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371212 · ClinicalTrials.gov registry record · Phase 4
A Prospective Randomized Controlled Trial of Dual-Mobility Components in Primary THA
A Phase 4 study of Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium, sponsored by Rush University Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT03371212: Active Phase 4 study of Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium, sponsored by Rush University Medical Center.
NCT03371212 is a Phase 4 study of Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium that is active but no longer recruiting, run by Rush University Medical Center. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03371212, a Phase 4 study of Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium, is active but no longer recruiting, sponsored by Rush University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine if the use of a modular dual mobility bearing is associated with clinically important increases in serum metal levels.
Primary Outcome
Assays for each subject for serum chromium in ug/L
Conditions Studied
Interventions
- DEVICE Dual mobility cohort
- DEVICE Conventional cohort
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2036-12-01 |
| Phase | Phase 4 |
What the registry record for NCT03371212 still lists
NCT03371212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium appearing as the primary indexed condition, and to 2 interventions - of which Dual mobility cohort is the first listed.
NCT03371212 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03371212 about?
NCT03371212 is a clinical study titled "A Prospective Randomized Controlled Trial of Dual-Mobility Components in Primary THA". The aim of this study is to determine if the use of a modular dual mobility bearing is associated with clinically important increases in serum metal levels.
What is the current status of trial NCT03371212?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2017-12-15. Estimated completion is 2036-12-01.
What conditions does trial NCT03371212 study?
This clinical trial studies the following conditions: Serum Metal Levels, Specifically Cobalt, Chromium, and Titanium.
What interventions are being tested in trial NCT03371212?
The interventions under investigation include: Dual mobility cohort (DEVICE), Conventional cohort (DEVICE).
Who is sponsoring clinical trial NCT03371212?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03371212 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03371212's enrollment target sits among peer trials
52 1233rd of 2000 higher than 753 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI